ADMA Biologics - ADMA Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.

2 brokers have issued 12-month target prices for ADMA Biologics' stock. Their ADMA share price forecasts range from $4.50 to $6.00. On average, they expect the company's share price to reach $5.25 in the next year. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.

ADMA Biologics' stock was trading at $3.88 at the start of the year. Since then, ADMA shares have decreased by 4.9% and is now trading at $3.69.
View the best growth stocks for 2023 here.

ADMA Biologics saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 12,050,000 shares, a decrease of 5.3% from the December 31st total of 12,720,000 shares. Based on an average trading volume of 3,290,000 shares, the short-interest ratio is currently 3.7 days.
View ADMA Biologics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ADMA earnings forecast.

ADMA Biologics, Inc. (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The biotechnology company had revenue of $41.09 million for the quarter, compared to analyst estimates of $34.57 million. ADMA Biologics had a negative trailing twelve-month return on equity of 52.73% and a negative net margin of 53.89%.

ADMA Biologics updated its FY 2022 earnings guidance on Saturday, January, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $153.00 million-$154.00 million, compared to the consensus revenue estimate of $148.95 million.

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.20%), First Hawaiian Bank (0.10%), AE Wealth Management LLC (0.01%), Verdence Capital Advisors LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends.

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMA stock can currently be purchased for approximately $3.69.

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $726.12 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

The company employs 527 workers across the globe.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.